Comparative assays for the HER-2/neu oncogene status in breast cancer.
作者： Luis Alberto Rubio-Martinez , José Maria Vera-Roman
DOI: 10.1043/1543-2165(2004)128<627:CAFTNO>2.0.CO;2
关键词: Oncogene 、 Her 2 neu oncogene 、 Biology 、 Cancer research 、 Breast cancer 、 Bioinformatics
摘要: Abstract Context.—Tumor marker assays, especially those used to indicate the right therapy, should be standardized. Objective.—To analyze current methods for HER-2/neu (h2n) oncogene status...
allenpress.com
archivesofpathology.org参考文章(39)
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
Daniel Harari, Yosef Yarden, Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. ,vol. 19, pp. 6102- 6114 ,(2000) , 10.1038/SJ.ONC.1203973
José Baselga, Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials Oncology. ,vol. 61, pp. 14- 21 ,(2001) , 10.1159/000055397
Sabine Glöckner, Hilke Buurman, Wolfram Kleeberger, Ulrich Lehmann, Hans Kreipe, Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Laboratory Investigation. ,vol. 82, pp. 1419- 1426 ,(2002) , 10.1097/01.LAB.0000032371.16521.40
Martine Piccart, Caroline Lohrisch, Angelo Di Leo, Denis Larsimont, The Predictive Value of HER2 in Breast Cancer Oncology. ,vol. 61, pp. 73- 82 ,(2001) , 10.1159/000055405
A. Thor, HER2 – a discussion of testing approaches in the USA Annals of Oncology. ,vol. 12, pp. 101- 107 ,(2001) , 10.1093/ANNONC/12.SUPPL_1.S101
A Vincent-Salomon, G MacGrogan, J Couturier, L Arnould, Y Denoux, M Fiche, J Jacquemier, M-C Mathieu, F Penault-Llorca, C Rigaud, P Roger, I Treilleux, M-O Vilain, S Mathoulin-Pelissier, V Le Doussal, Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. ,vol. 42, pp. 337- 347 ,(2003) , 10.1046/J.1365-2559.2003.01598.X
A Bankfalvi, R Simon, B Brandt, H Burger, I Vollmer, B Dockhorn-Dworniczak, R-J Lelle, W Boecker, Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology. ,vol. 37, pp. 411- 419 ,(2000) , 10.1046/J.1365-2559.2000.00984.X
O. P. Kallioniemi, A. Kallioniemi, W. Kurisu, A. Thor, L. C. Chen, H. S. Smith, F. M. Waldman, D. Pinkel, J. W. Gray, ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 5321- 5325 ,(1992) , 10.1073/PNAS.89.12.5321
Jérôme Couturier, Anne Vincent-Salomon, André Nicolas, Philippe Beuzeboc, Emmanuelle Mouret, Brigitte Zafrani, Xavier Sastre-Garau, Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/ neu ) Gene Status in Breast Carcinoma Modern Pathology. ,vol. 13, pp. 1238- 1243 ,(2000) , 10.1038/MODPATHOL.3880228